Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

Sally Hopewell and John Christianson

Sally works within OCTRU as Professor of Clinical Trials and Evidence Synthesis. She is involved in leading the design and delivery of clinical trials within the OCTRU portfolio. She is also co-chief investigator on several NIHR funded trials for interventions for people with shoulder pain and impaired shoulder function. Her key areas of research expertise are in the design, conduct and transparent reporting of randomized trials and systematic reviews.  

On receiving the award, Sally said “I am honoured and proud to receive this award and title Professor as part of this year’s Recognition of Distinction exercise. 

To me, this award shows recognition of the importance of conducting high quality trial methodology research and how it can be used to inform the design, conduct and reporting of future clinical trials; such as those carried out by the Oxford Clinical Trials Research Unit (OCTRU) and Centre for Statistics in Medicine (CSM).  

I am very grateful of the invaluable support I have received during my academic career and also pleased to add to the increasing number of female Professors within the Medical Sciences Division. I hope to inspire and encourage others to pursue a career in trial methodology research.”   

John is Professor and CRUK Senior Research Fellow in the Oppermann Group. His research investigates the fundamental mechanisms and effects of cellular stress on cancers and many other diseases. His work explores new strategies for cancer intervention to prevent the progression of the disease.

He said “It is a great privilege to become a full professor at the University of Oxford. I owe this achievement to the hard work and tenacity of my DPhil students and post-docs, who have breathed the life into our research that enables it to flourish.”  

Similar stories

Study challenges fears over blood-clot risk from painkillers and hormonal contraception

Women using hormonal contraception who are prescribed common anti-inflammatory painkillers may not face a drug-related increase in blood-clot risk despite previous research, according to a new DARWIN EU® study.

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8th October 2026.

Adam Croft appointed Norman Collisson Professor of Musculoskeletal Science

This appointment brings a further focus to linking rheumatology discovery science and clinical trials in NDORMS, strengthening translational rheumatology research across the department to deliver transformative treatments for patients with inflammatory arthritis.

NIHR fellowship to support national trial evaluating rehabilitation after kneecap dislocation

Dr Colin Forde has been awarded a National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Postdoctoral Award to lead a national study evaluating rehabilitation for people with a kneecap (patellar) dislocation.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Professor Afsie Sabokbar retires after more than 30 years at NDORMS

Botnar Institute Director of Graduate Studies, Professor Afsie Sabokbar, is retiring after more than 30 years at NDORMS.